Buchumschlag

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase‐1 in Children With Cystic Fibrosis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Senthilkumar Sankararaman, Leesa Prunty, Catherine Pamer, Aravind Thavamani, Erica Roesch, Teresa Schindler
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Pediatric Pulmonology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis
von: Sara Kümmerli, et al.
Veröffentlicht: (2026)

Utility of Fecal Elastase‐1 in Estimating Exocrine Pancreatic Function in Cystic Fibrosis: A Scoping Review
von: Senthilkumar Sankararaman, et al.
Veröffentlicht: (2026)

Effects of Elexacaftor‐Tezacaftor‐Ivacaftor on Nasal and Sinus Symptoms in Children With Cystic Fibrosis
von: Guillaume Petit, et al.
Veröffentlicht: (2025)

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis
von: Cindy L. Williams, et al.
Veröffentlicht: (2025)

Real‐World Impact of Elexacaftor/Tezacaftor/Ivacaftor in Israeli Children Aged 2–6 With Cystic Fibrosis
von: Adi Dagan, et al.
Veröffentlicht: (2026)

Papilledema in Children With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Case Series
von: Charissa W. Kam, et al.
Veröffentlicht: (2024)

Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis
von: Burcu Uzunoglu, et al.
Veröffentlicht: (2025)

The Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study
von: Sasha‐Jane Abi‐Aad, et al.
Veröffentlicht: (2026)

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis
von: Christos Kogias, et al.
Veröffentlicht: (2026)

Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy
von: Kimberly Pasley, et al.
Veröffentlicht: (2024)

A Tale of Two Infants: Off‐Label Use of Elexacaftor/Tezacaftor/Ivacaftor in Early Cystic Fibrosis Treatment
von: Nour K. Kadouh, et al.
Veröffentlicht: (2025)

Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis
von: Emma R. Lyons, et al.
Veröffentlicht: (2025)

Real World Adverse Effects of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis Ages 6–11 Years
von: Rebecca S. Pettit, et al.
Veröffentlicht: (2025)

Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States
von: Sonia Graziano, et al.
Veröffentlicht: (2025)

Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation
von: Esben Herborg Henriksen, et al.
Veröffentlicht: (2025)

Improving Pancreatic Function With Elexacaftor/Tezacaftor/Ivacaftor
von: Madison Pranske, et al.
Veröffentlicht: (2026)

Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross‐Sectional Single‐Centre Study
von: Lauren J. Clayton, et al.
Veröffentlicht: (2025)

Effects of an Exercise Intervention on Exercise Capacity in Adults With Cystic Fibrosis: A Quasi‐Experimental Study Comparing Individuals Treated With and Without Elexacaftor/Tezacaftor/Ivacaftor
von: Wolfgang Gruber, et al.
Veröffentlicht: (2025)

Crushing Elexacaftor/Tezacaftor/Ivacaftor Oral Granules for Gastrostomy Tube Administration
von: Alexander S. Kim, et al.
Veröffentlicht: (2025)

Diabetes remission in adults with cystic fibrosis commenced on Elexacaftor/Tezacaftor/Ivacaftor: A single center case‐series
von: Shanal Kumar, et al.
Veröffentlicht: (2024)

Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients
von: Jochen G. Mainz, et al.
Veröffentlicht: (2026)

Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center
von: Lena Papadakis, et al.
Veröffentlicht: (2024)

Cautious Interpretation of RCT Evidence
von: Senthilkumar Sankararaman, et al.
Veröffentlicht: (2026)

Variable Response to Elexacaftor/Tezacaftor/Ivacaftor in [L467F;F508del] Homozygous Patients: A Case Series
von: Meltem Akgül Erdal, et al.
Veröffentlicht: (2026)

Lung T1‐MRI and Multi‐Breath Washout Detect Longitudinal Changes in Children 6–11 Years Old After Beginning Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy
von: Samya Z. Nasr, et al.
Veröffentlicht: (2026)

Elexacaftor/Tezacaftor/Ivacaftor Effect on a Patient With Rare Compound Heterozygous CFTR Splice Variant Genotype C.[1393‐1G>A;2988+1G>A]
von: Maria Moustaki, et al.
Veröffentlicht: (2025)

Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real‐Life Study
von: A. M. Zwitserloot, et al.
Veröffentlicht: (2025)

Effects of Therapeutic Antibiotic Exposure on the Oropharyngeal and Fecal Microbiota in Infants With Cystic Fibrosis
von: Hillary S. Hayden, et al.
Veröffentlicht: (2025)

Lung clearance index (LCI2.5) changes after initiation of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis aged between 6 and 11 years: The “real‐world” differs from trial data
von: Don S. Urquhart, et al.
Veröffentlicht: (2024)

“No Words for Feelings”: Alexithymia in Children With Cystic Fibrosis and Their Caregivers
von: Tuğba Şişmanlar Eyüboğlu, et al.
Veröffentlicht: (2026)

Impact of Number of Pharmacies on Dornase Alfa Medication Possession Ratio in Children With Cystic Fibrosis
von: Rebecca S. Pettit, et al.
Veröffentlicht: (2025)

Hospitalizations in Infants and Young Children With Cystic Fibrosis Enrolled in Medicaid
von: Laurie P. Murray, et al.
Veröffentlicht: (2025)

Impact of Home Collection and Shipping of Respiratory Specimens on Bacterial Pathogen Detection in Children With Cystic Fibrosis
von: Jordana E. Hoppe, et al.
Veröffentlicht: (2025)

Fueling Health: Overcoming Food Barriers in Cystic Fibrosis Care
von: Brittany A. Wright, et al.
Veröffentlicht: (2025)

The Frequency and Potential Implications of HFE Genetic Variants in Children With Cystic Fibrosis
von: Leslie Huang, et al.
Veröffentlicht: (2025)

Objectively Monitored Sleep in School‐Age Children With Cystic Fibrosis and Their Parents
von: Andrea L. Fidler, et al.
Veröffentlicht: (2025)

Commentary on “Impact of Home Collection and Shipping of Respiratory Specimens on Bacterial Pathogen Detection in Children With Cystic Fibrosis”
von: Ahmet Kağan Özkaya, et al.
Veröffentlicht: (2025)

The Impact of Cystic Fibrosis‐Related Diabetes on Barriers to Self‐Management
von: Rebecca J. Vitale, et al.
Veröffentlicht: (2026)

Interrater Reliability of a Modified Bronchoscopy Scoring Tool in Children With Cystic Fibrosis
von: Alexandra Bosetti, et al.
Veröffentlicht: (2025)

Increasing Cystic Fibrosis Knowledge of Parents of Children Diagnosed With the Newborn Screening Program
von: Mine Yüksel Kalyoncu, et al.
Veröffentlicht: (2025)